Feed LLY
LL

Eli Lilly

LLY · NYSE

$1,115.23 -0.69% (-$7.77)
1M -5.50%
Market Cap $1.09T
P/E Ratio 40.88x
Div. Yield 0.56%
ROE 92.58%

Bulios Fair Price

$928.82

16.7% downside

Trenutna cena

$1,115

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica LLY trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Strong
8/9
Valuation
11 /100
Expensive
P/E 40.88x
EV/EBITDA 32.32x
P/S 13.71x
Growth
100 /100
Growing
EPS growth 51.73%
Rev. growth 31.69%
FCF growth 24.94%
Profitability
100 /100
Strong
Gross margin 84.01%
Net margin 33.53%
Op. margin 43.92%
Quality
92 /100
Excellent
ROIC 27.38%
ROE 92.58%
ROA 18.77%
Debt
67 /100
Low
Debt/Equity 1.62x
Current ratio 1.35x
Int. coverage 34.79x
Stability
64 /100
Moderate
Beta 0.50x
Rev. volatility 12.57%
EPS volatility 63.96%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o LLY
Online

O podjetju

Eli Lilly and Company (LLY) is an American pharmaceutical company with a long history and significant influence in the global pharmaceutical market. The company specializes in research, development, and manufacturing of medicinal products in various therapeutic areas, including diabetology, oncology, neurology, and others. Eli Lilly offers a wide range of pharmaceutical products and treatment approaches that help improve the health and quality of life of patients worldwide. The company invests in innovation and research to bring new drugs and treatment methods that could potentially change the way diseases are treated. Eli Lilly and Company is a respected name in the pharmaceutical industry and has a strong foundation for further growth and development. Investing in Eli Lilly and Company (LLY) shares may represent an attractive choice for investors seeking a reliable and innovative company in the healthcare sector.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

David A. Ricks

Employees

50,000

Headquarters

Indianapolis

Prihajajoči dogodki

29 OKT.

Earnings

Upcoming earnings report

46d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.